The 2017 American Society of Clinical Oncology (ASCO) Annual Meeting will take place on 2–6 June 2017 at McCormick Place convention centre, Chicago, Illinois.
Boehringer Ingelheim will be presenting overall survival analysis of the LUME-Meso trial, results of the Phase III LUX-Head and Neck 2 trial and results of the first-in-man Phase I trial of the novel BET inhibitor, BI894999. For more details, please see below. The full ASCO 2017 programme can be found here.
Let’s collaborate at ASCO 2017 – visit us at booth 21081
At Boehringer Ingelheim we believe that when it comes to outsmarting cancer, we’re brighter together. Visit us at booth 21081 to find out more about our collaborative approach to research and our oncology pipeline.
A healthy diet is important for us all, including people living with cancer. Come and visit us in the nutrition corner where we want to demonstrate a partnership we have been working on to help highlight the importance of healthy diet for your patients.